Company Overview of Seaside Therapeutics, LLC
Seaside Therapeutics, LLC engages in the development of drugs to correct or improve the course of autism, fragile X syndrome, and other neurodevelopmental disorders. The company focuses on translating discoveries in neurobiology into therapeutics. Its products include STX209, a selective gamma-amino butyric acid type-B receptor agonist to serve STX209 to restore the normal balance at the synapse and correct abnormalities associated with autism and fragile X syndrome disorders; and STX107, a selective mGluR5 antagonist modulator. The company’s programs also include biomarker research, next generation mGlur5 negative allosteric modulator, and muscarinic acetylcholine receptor modulator. Seasid...
840 Memorial Drive
Cambridge, MA 02139
Founded in 2005
Key Executives for Seaside Therapeutics, LLC
Co-Founder, Chief Executive Officer, President and Director
Scientific Founder and Advisor
Vice President of Manufacturing & Process Development
Vice President of Clinical Operations
Vice President of Clinical Development
Compensation as of Fiscal Year 2015.
Seaside Therapeutics, LLC Key Developments
Seaside Therapeutics, LLC Presents at 2014 Autism Investment Conference, Mar-04-2014 11:15 AM
Mar 1 14
Seaside Therapeutics, LLC Presents at 2014 Autism Investment Conference, Mar-04-2014 11:15 AM. Venue: Bently Reserve, 301 Battery St, San Francisco, CA 94111, United States. Speakers: Randall L. Carpenter, Co-Founder, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries